Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Acute mania in patient under tamoxifen

View through CrossRef
IntroductionTamoxifen is an antioestrogen agent used in breast cancer treatment. According to some guidelines, this molecular was also proposed for the treatment of acute mania. In fact, Tamoxifen inhibits the intracellular action of the protein kinase C (PKC), which is the direct target in the treatment of mania episodes. Lithium and valproate have also the same action.ObjectivesWe aimed to show the case of an acute mania under an inhibitor PKC treatment and insisted that other studies are recommended.MethodsCase report description and research on medline, pubmed with the keywords: Tamoxifen, Bipolar disorder, protein kinase C,mania.ResultsWe reported a case of a 53-year-old woman with past history of unipolar depression. In 2018 when she was diagnosed with breast cancer. She received antidepressant drugs but she interrupted the treatment after a few months. She was treated for her breast cancer with mastectomy, radiotherapy, and 20 mg per day of Tamoxifen prescribed since Mars 2018. She had been admitted in June 2019 in our department for acute mania. The patient received Tamoxifen as it was prescribed. She was not taking any concomitant medications. No history of drug abuse was reported. Medical examination, laboratory, and radiological investigations did not indicate any medical pathology.ConclusionsIn our case, Tamoxifen had not ovoid the acute mania in spite of its Known anti-manic properties as reported in the literature. Possible neurobiological effect of tamoxifen on the nervous system should be studied to evaluate the safety of this treatment mainly in patients with bipolar disorder.
Title: Acute mania in patient under tamoxifen
Description:
IntroductionTamoxifen is an antioestrogen agent used in breast cancer treatment.
According to some guidelines, this molecular was also proposed for the treatment of acute mania.
In fact, Tamoxifen inhibits the intracellular action of the protein kinase C (PKC), which is the direct target in the treatment of mania episodes.
Lithium and valproate have also the same action.
ObjectivesWe aimed to show the case of an acute mania under an inhibitor PKC treatment and insisted that other studies are recommended.
MethodsCase report description and research on medline, pubmed with the keywords: Tamoxifen, Bipolar disorder, protein kinase C,mania.
ResultsWe reported a case of a 53-year-old woman with past history of unipolar depression.
In 2018 when she was diagnosed with breast cancer.
She received antidepressant drugs but she interrupted the treatment after a few months.
She was treated for her breast cancer with mastectomy, radiotherapy, and 20 mg per day of Tamoxifen prescribed since Mars 2018.
She had been admitted in June 2019 in our department for acute mania.
The patient received Tamoxifen as it was prescribed.
She was not taking any concomitant medications.
No history of drug abuse was reported.
Medical examination, laboratory, and radiological investigations did not indicate any medical pathology.
ConclusionsIn our case, Tamoxifen had not ovoid the acute mania in spite of its Known anti-manic properties as reported in the literature.
Possible neurobiological effect of tamoxifen on the nervous system should be studied to evaluate the safety of this treatment mainly in patients with bipolar disorder.

Related Results

Risk of Death Due to Breast Cancer in Women Treated with Selective Serotonin Reuptake Inhibitor Antidepressants and Tamoxifen.
Risk of Death Due to Breast Cancer in Women Treated with Selective Serotonin Reuptake Inhibitor Antidepressants and Tamoxifen.
Abstract Background: Tamoxifen is widely prescribed to women with breast cancer, but is a prodrug converted by cytochrome P450 2D6 (CYP 2D6) to its active metabolite...
miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22
miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22
Background/Aims: Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selecti...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Morphological and morphometric analysis of the effects of intralesional tamoxifen on keloids
Morphological and morphometric analysis of the effects of intralesional tamoxifen on keloids
The aim of this study was to evaluate the effect of intralesional tamoxifen on keloids, particularly on the concentration of fibroblasts, dermal inflammatory infiltrate, and collag...
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Abstract Abstract #3020 Background: Overexpression and altered function of EphA2 receptor tyrosine kinase are critical in the progression of breast ca...
P01-08 - Mania, Mania with Delirium and Delirious Mania
P01-08 - Mania, Mania with Delirium and Delirious Mania
Since Bell's original description delirious mania (DM) has been repeatedly rediscovered and renamed, resulting in much confusion as to its meaning.Definitions range from mania with...

Back to Top